tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate | 1013334-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate
• CAS: 1013334-09-2
• 化学式: C₂₄H₃₇NO₅Si
• 分子量: 447.647
• InChiKey: XBVKYXBJHYVJDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.81
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-苯基双(三氟甲烷磺酰)亚胺 、 tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 Tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-(trifluoromethylsulfonyloxy)spiro[chromene-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

  摘要：

  Selective 6 opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable 6 agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

  DOI：

  10.1021/jm8008986
• 作为产物：
  描述：

  tert-butyl 8-hydroxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 8-[tert-butyl(dimethyl)silyl]oxy-4-oxospiro[3H-chromene-2,4'-piperidine]-1'-carboxylate
  参考文献：
  名称：

  Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

  摘要：

  Selective 6 opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable 6 agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

  DOI：

  10.1021/jm8008986